COMPANY

 


INNOVATION FOR LIFE

 

 

EVERY MINUTE COUNTS

Exact results with GPBB in 10 minutes

 

ADVANCED TECHNOLOGY

High precision, reliable and meaningful results

 

LOW COSTS

Exact diagnosis without expensive and long-term laboratory methods

 

SIMPLE USE

Simple use recognizing the risk within 10 minutes

 

 

 

DiagenicsLogoKlein.jpg

Diagenics Group SE is a biopharmaceutical enterprise with branch offices and partners in Europe and the USA. We are developers and producers of a new product line of diagnostic tools based on a new and innovative bio-marker. The potential of our products will change and improve the medical diagnosis. With the help of our new products, not only are we capable of diagnose a myocardial infarction - also known as ACS (Acute Coronary Syndrome) - quicker and more accurately, but also can we perform faster, safer and more effectively. The health system can also benefit from it, as cost-effectiveness can be increased by getting earlier and more precise resources and by reducing the frequency of misdiagnosis.


While our main focus is on early detection of heart attack, we are also currently developing diagnostic devices for early detection of strokes and preeclampsia (a widespread pregnancy complication). It is not difficult to imagine that by developing promising and new diagnostic technology for the two largest fields of disease in the world, the influence of our products on the world market will be immense.

Anyone can have a heart attack. When the blood flow in the heart is disrupted (ischemia), usually caused by a clot in a vessel, the oxygen supply to the heart is disturbed and after a short time the affected heart muscle cells begin to die. This leads to a so-called acute myocardial infarction (AMI) or heart attack.

In this situation, every second counts, but the classic biomarker can only detect an incipient necrosis, which means it is already too late. Here, our new method provides the solution for an early yet specific diagnosis of a myocardial infarction. The enzyme, which we detect by antibodies in the blood, bears the name Glycogen phosphorylase BB (GPBB). It acts as a safety valve for the cells in the heart, letting them survive for some time without oxygen. The inactive form of GPBB is localized in the heart muscle cells and is activated by a biochemical cascade and released into the blood in case of lack of oxygen. This activated form can now be detected by our antibodies in the blood.

This, GPBB is the earliest heart-specific biomarker in heart problems. Opposed to the classical biomarker troponin, returns to base value within 18-24 hours, so after that, any re-infarction or success of treatment e.g. a stent can always be monitored by GPBB concentration in the patient’s blood.

 

 


COMPANY HISTORY AND HIGHLIGHTS

 


2002

Diagenics Group Inc. - founded in Boston, US


2006

Production of the

Diacordon® - POCT (rapid test)

2009

Diagenics Group SE - founded in Luxembourg /

Development of the comb. tests ( POCT Plus T)

2015

New Products:

Diastroke® and Dianeonatal® - POCT

2017

Filing of Patent GPBB Epitope Mapping

2019

Listing at SIX - Swiss Exchange /

Preparation of the IPO